Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells

Prostate

Volumn 71, Issue 9, 2011, Pages 964-975

  Hoshino, Koji ^a   Ishiguro, Hitoshi ^a,b   Teranishi, Jun Ichi ^a   Yoshida, Shin Ichiro ^a   Umemura, Satoshi ^a   Kubota, Yoshinobu ^a   Uemura, Hiroji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

androgen receptor; angiotensin II receptor; prostate cancer; siRNA

Indexed keywords

ANDROGEN RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; NF-KAPPA B; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, SMALL INTERFERING;

EID: 79955619065     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21312     Document Type: Article

References (58)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report. Int J Urol 2005; 12 (1): 46-61.
3. Miyamoto H, Messing EM, Chang C,. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004; 61 (4): 332-353. (Pubitemid 39571710)
4. Miyoshi Y, Uemura H, Fujinami K, Mikata K, Harada M, Kitamura H, Koizumi Y, Kubota Y,. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000; 43 (3): 225-232. (Pubitemid 30230459)
5. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP,. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332 (21): 1393-1398.
6. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F,. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8 (11): 3438-3444. (Pubitemid 35340719)
7. Morris GL, Dodd JG,. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 1990; 143 (6): 1272-1274. (Pubitemid 20193105)
8. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN,. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003; 100 (5): 2645-2650. (Pubitemid 36297552)
9. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA,. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000; 6 (6): 2295-2308. (Pubitemid 30399196)
10. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR,. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006; 99 (2): 392-401. (Pubitemid 44435557)
11. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z,. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58 (20): 4640-4645. (Pubitemid 28480629)
12. Chen T, Wang LH, Farrar WL,. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000; 60 (8): 2132-2135. (Pubitemid 30225173)
13. Ueda T, Bruchovsky N, Sadar MD,. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277 (9): 7076-7085. (Pubitemid 34959964)
14. Lin DL, Whitney MC, Yao Z, Keller ET,. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 2001; 7 (6): 1773-1781. (Pubitemid 32708648)
15. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y,. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003; 2 (11): 1139-1147.
16. Clere N, Corre I, Faure S, Guihot AL, Vessieres E, Chalopin M, Morel A, Coqueret O, Hein L, Delneste Y, Paris F, Henrion D,. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer 2010; 127 (10): 2279-2291.
17. Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y,. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006; 66 (8): 822-830.
18. Chung O, Kuhl H, Stoll M, Unger T,. Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int Suppl 1998; 67: S95-99. (Pubitemid 28405689)
19. Dzau VJ,. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens Suppl 1994; 12 (4): S3-S10. (Pubitemid 24247672)
20. Huckle WR, Earp HS,. Regulation of cell proliferation and growth by angiotensin II. Prog Growth Factor Res 1994; 5 (2): 177-194.
21. Rosendorff C,. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996; 28 (4): 803-812. (Pubitemid 26348140)
22. Tahmasebi M, Puddefoot JR, Inwang ER, Goode AW, Carpenter R, Vinson GP,. Transcription of the prorenin gene in normal and diseased breast. Eur J Cancer 1998; 34 (11): 1777-1782. (Pubitemid 28474235)
23. Nelson J, Bagnato A, Battistini B, Nisen P,. The endothelin axis: Emerging role in cancer. Nat Rev Cancer 2003; 3 (2): 110-116. (Pubitemid 37328878)
24. Uemura H, Ishiguro H, Nagashima Y, Sasaki T, Nakaigawa N, Hasumi H, Kato S, Kubota Y,. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther 2005; 4 (11): 1699-1709. (Pubitemid 41685304)
25. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y,. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 2005; 10 (6): 405-410. (Pubitemid 41821524)
26. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, Goto S, Imaizumi K, Hisada Y, Otsuka A, et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 1995; 270 (32): 18719-18722.
27. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, Fukamizu A, Murakami K,. Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994; 269 (50): 31334-31337. (Pubitemid 24379482)
28. Hasumi H, Ishiguro H, Nakamura M, Sugiura S, Osada Y, Miyoshi Y, Fujinami K, Yao M, Hamada K, Yamada-Okabe H, Kubota Y, Uemura H,. Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival. Int J Cancer 2005; 115 (6): 911-916. (Pubitemid 40791831)
29. Ishiguro H, Uemura H, Fujinami K, Ikeda N, Ohta S, Kubota Y,. 55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor. Int J Cancer 2003; 105 (1): 26-32. (Pubitemid 36418481)
30. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I,. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6 (6): 499-506. (Pubitemid 38786592)
31. Tamura K, Yokoyama N, Sumida Y, Fujita T, Chiba E, Tamura N, Kobayashi S, Kihara M, Murakami K, Horiuchi M, Umemura S,. Tissue-specific changes of type 1 angiotensin II receptor and angiotensin-converting enzyme mRNA in angiotensinogen gene-knockout mice. J Endocrinol 1999; 160 (3): 401-408. (Pubitemid 29182831)
32. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K,. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 2001; 495 (3): 197-200. (Pubitemid 32397704)
33. Chen YF, Naftilan AJ, Oparil S,. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992; 19 (5): 456-463.
34. Phillips MI, Speakman EA, Kimura B,. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993; 43 (1-2): 1-20.
35. Neylon M, Marshall J, Johns EJ,. The role of the renin-angiotensin system in the renal response to moderate hypoxia in the rat. J Physiol 1996; 4913 (Pt 2): 479-488. (Pubitemid 26081737)
36. Leung PS, Carlsson PO,. Tissue renin-angiotensin system: Its expression, localization, regulation and potential role in the pancreas. J Mol Endocrinol 2001; 26 (3): 155-164. (Pubitemid 32514606)
37. Ip SP, Wong TP, Tsai SJ, Leung PS,. The recovery of some components of the renin angiotensin system in the rat pancreas after chronic exposure to hypoxic condition. J Mol Endocrinol 2003; 31 (3): 563-571. (Pubitemid 38054526)
38. Uemura H, Ishiguro H, Kubota Y,. Angiotensin II receptor blocker: Possibility of antitumor agent for prostate cancer. Mini Rev Med Chem 2006; 6 (7): 835-844. (Pubitemid 44027736)
39. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW,. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43 (5): 993-1002. (Pubitemid 38579904)
40. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA,. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270 (22): 12953-12956.
41. Rosen ED, Spiegelman BM,. PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276 (41): 37731-37734.
42. Willson TM, Brown PJ, Sternbach DD, Henke BR,. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000; 43 (4): 527-550. (Pubitemid 30127149)
43. Berger J, Moller DE,. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-435. (Pubitemid 34177889)
44. Picard F, Auwerx J,. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002; 22: 167-197.
45. Walczak R, Tontonoz P,. PPARadigms and PPARadoxes: Expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 2002; 43 (2): 177-186. (Pubitemid 34184004)
46. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H,. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007; 67 (9): 924-932. (Pubitemid 46828926)
47. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ,. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics. J Clin Oncol 2002; 20 (8): 2171-2180. (Pubitemid 34408809)
48. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA,. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100 (19): 10954-10959. (Pubitemid 37140134)
49. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA,. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55 (5): 1112-1123.
50. Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ,. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008; 14 (19): 6270-6276.
51. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M,. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113 (9): 2478-2487.
52. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, Cher M, Sarkar FH,. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007; 67 (8): 3818-3826. (Pubitemid 46762169)
53. Lee JG, Zheng R, McCafferty-Cepero JM, Burnstein KL, Nanus DM, Shen R,. Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Mol Carcinog 2009; 48 (2): 141-149.
54. Daaka Y,. G proteins in cancer: The prostate cancer paradigm. Sci STKE 2004; 2004 (216): re2.
55. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, Lin MF, Tu Y,. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 2006; 25 (26): 3719-3734. (Pubitemid 43980493)
56. Culig Z, Steiner H, Bartsch G, Hobisch A,. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005; 95 (3): 497-505. (Pubitemid 41420180)
57. Lee LF, Guan J, Qiu Y, Kung HJ,. Neuropeptide-induced androgen independence in prostate cancer cells: Roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001; 21 (24): 8385-8397. (Pubitemid 33108599)
58. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ,. Interleukin-8 confers androgen-independent growth and migration of LNCaP: Differential effects of tyrosine kinases Src and FAK. Oncogene 2004; 23 (12): 2197-2205. (Pubitemid 38482534)